{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123437","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.304230+00:00","generated_at":"2026-05-30T03:39:27.267653+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029","bullets":["Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.","Cash and cash equivalents at Sept. 30, 2024: $334.5M, with additional $27.6M from underwriter option in Oct. 2024.","IPO and concurrent private placement yielded ~$189.5M net, plus $27.6M from underwriter option; cash sufficient into 2029.","Phase 2 STRIDES trial of azelaprag + tirzepatide for obesity dosed first patient; top-line results expected Q3 2025.","Appointed former GSK CEO Jean-Pierre Garnier as Board Chair, succeeding James Healy who remains a director."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123437","json":"https://secwatch.observer/filing/0000950170-24-123437.json","markdown":"https://secwatch.observer/filing/0000950170-24-123437.md","text":"https://secwatch.observer/filing/0000950170-24-123437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000095017024123437/0000950170-24-123437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000095017024123437/bioa-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:39:27.267653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}